Capricor FY2025 net loss $105M; Deramiocel PDUFA date Aug 22, 2026

CAPRICOR THERAPEUTICS, INC.

Net loss of $30.2M in Q4 2025 ($0.62/sh) and $105.0M for FY2025 ($2.26/sh).
Revenue was $0 in Q4 and FY2025, vs $11.1M and $22.3M in prior-year periods, as Nippon Shinyaku milestones fully recognized.
Cash, equivalents and marketable securities $318.1M at Dec 31, 2025, up from $151.5M; expected to fund operations through 2027.
BLA for Deramiocel in Duchenne muscular dystrophy under FDA review; PDUFA target date August 22, 2026.
Phase 3 HOPE-3 trial met primary endpoint (PUL v2.0, p=0.03) and key cardiac endpoint (LVEF, p=0.04).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CAPRICOR THERAPEUTICS, INC. reported the fourth quarter ended December 31, 2025 results: revenue $0.

Period: the fourth quarter ended December 31, 2025
Revenue: $0
Result: reported results

Exact text from the filing

Revenues for the fourth quarter of 2025 were $0

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

CAPRICOR THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001104659-26-027037

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.